NCT06890832 - A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Metastatic Castration-resistant Prostate Cancer, MCRPC

Interventions

DRUG

50 mg cabazitaxel

50 mg cabazitaxel to be taken every week for 6 cycles (3 doses per cycle), 10 mg prednisone to be taken daily till end of cycle 6

DRUG

100 mg cabazitaxel

100 mg cabazitaxel to be taken every week for 6 cycles (3 doses per cycle), 10 mg prednisone to be taken daily till end of cycle 6

DRUG

200 mg cabazitaxel

200 mg cabazitaxel to be taken every 3-week for 6 cycles (1 dose per cycle), 10 mg prednisone to be taken daily till end of cycle 6